Case Report

Asacol®-induced Neutropenia Resolution Without the Use of Granulocyte Colony-stimulating Factor

Authors: Brian T. Fowler, MD, Tina Gupta, BA, Muhammad Bilal, MD

Abstract

We report a case of neutropenia and gram-negative septicemia in a 73-year-old male with ulcerative colitis. During the hospital course, medications were adjusted according to rare accounts of drug-induced neutropenia. While the substitution of propafenone for another antiarrhythmic brought about no change in the patient's absolute neutrophil count, the cessation of Asacol® (Warner Chilcott, Rockaway, NJ) was followed by a significant improvement in the neutropenic state. In fact, this neutrophil count continued to trend upward for months following. We thereby conclude that Asacol® carries the potential to induce neutropenia and that this reaction may be reversed in some patients solely by discontinuing the medication and without the aid of stimulating factors such as filgrastim.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Sweetman S. Martindale: The Complete Drug Reference (electronic version). London, Pharmaceutical Press, ed 34, 2004.
 
 
2. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis [review]. Aliment Pharmacol Ther 2004;19:179–189.
 
 
3. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536–9.
 
 
4. Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:647–662.
 
5. Jick H, Wald Myers M, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995;15:176–181.
 
 
6. Wyatt S, Joyner MV, Daneshmend TK. Filgrastim for mesalazine-associated neutropenia. Lancet 1993;341:1476.
 
7. Bhidayasiri R, Katz JA, Sokos DR. Correction of mesalazine-induced neutropenia with high-dose G-CSF. Am J Gastroenterol 2000;95:3321–3322.
 
8. Delgado-Riley AM, Roger V, Zabeleta IA, et al. Mesalamine associated neutropenia in a newborn. Int Pediatr 2002;17:54–56.
 
 
9. Kotanagi H, Ito M, Koyama K, et al. Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease. J Gastroenterol 1998;33:571–574.
 
10. Turunen U, Elomaa I, Anttila VJ, et al. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scan J Gastroenterol 1987;22:798–802.
 
11. Marteau P, Nelet F, Le Lu M, et al. Adverse events in patients treated with 5-aminosalicyclic acid: 1993–1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996;10:949–956.